Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report

Surena F. Matin, Phillip M. Pierorazio, Nir Kleinmann, John L. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott G. Hubosky, Marcelino Rivera, Michael O'Donnell, Marcus Quek, Jay D. Raman, John J. Knoedler, Douglas Scherr, Christopher Weight, Alon Weizer, Michael Woods, Hristos Kaimakliotis, Angela B. SmithJennifer Linehan, Jonathan Coleman, Mitchell R. Humphreys, Raymond Pak, David Lifshitz, Michael Verni, Ifat Klein, Marina Konorty, Dalit Strauss-Ayali, Gil Hakim, Elyse Seltzer, Mark Schoenberg, Seth P. Lerner

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)779-788
Number of pages10
JournalThe Journal of urology
Volume207
Issue number4
DOIs
StatePublished - Apr 1 2022

ASJC Scopus Subject Areas

  • Urology

Keywords

  • clinical trial
  • mitomycin
  • urinary bladder neoplasms

Cite this